# OnCo record mpact (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/mpact/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "mpact", "NCT00844649" ;
  schema:name "MPACT"@en ;
  schema:alternateName "CA046"@en, "Metastatic Pancreatic Adenocarcinoma Clinical Trial"@en ;
  schema:description "MPACT established the second modern first-line regimen for advanced pancreatic cancer: adding albumin-bound paclitaxel to gemcitabine lengthened median survival from 6.7 to 8.5 months and doubled two-year survival, with more neuropathy and neutropenia; it is the option for people not fit enough for FOLFIRINOX and the control arm of most trials since."@en ;
  schema:url <https://onco.cc/trials/mpact/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT00844649>, <https://doi.org/10.1056/NEJMoa1304369>, <https://doi.org/10.1093/jnci/dju413>, <https://api.fda.gov/drug/label.json?search=openfda.brand_name:%22ABRAXANE%22> ;
  onco:status "positive" ;
  onco:phase "3" ;
  onco:cancers <https://onco.cc/cancers/pancreatic/>, <https://onco.cc/cancers/metastatic-pdac/> ;
  onco:technologies <https://onco.cc/technologies/cytotoxic-chemotherapy/> ;
  onco:drugs <https://onco.cc/drugs/gemcitabine-nab-paclitaxel/>, <https://onco.cc/drugs/nab-paclitaxel/>, <https://onco.cc/drugs/gemcitabine/> ;
  onco:companies <https://onco.cc/companies/bms/> ;
  onco:terms <https://onco.cc/terms/peripheral-neuropathy/>, <https://onco.cc/terms/neutropenia/>, <https://onco.cc/terms/ca19-9/> ;
  onco:people <https://onco.cc/people/daniel-von-hoff/> .